SCHEMBL25865729

SCHEMBL25865729

[N-]=[N+]=NCCOCCOCCOc1c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c2c1=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLH Q9Y253 7/20 0.70
▸ MEN1 O00255 4/20 0.59
▸ KMT2A Q03164 4/20 0.59
▸ KDM4E B2RXH2 4/20 0.59
▸ POLB P06746 4/20 0.59
▸ GAA P10253 4/20 0.59
▸ RECQL P46063 3/20 0.59
▸ HSD17B10 Q99714 3/20 0.59
▸ MAPT P10636 3/20 0.59
▸ MMP1 P03956 2/20 0.59
▸ APEX1 P27695 2/20 0.59
▸ BLM P54132 2/20 0.59
▸ HTT P42858 1/20 0.59
▸ ABCG2 Q9UNQ0 4/20 0.53
▸ EPHX2 P34913 3/20 0.53
▸ AKR1B1 P15121 3/20 0.53
▸ NOX4 Q9NPH5 3/20 0.53
▸ USP2 O75604 2/20 0.53
▸ TP53 P04637 2/20 0.53
▸ CYP1A2 P05177 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20630933 0.86 POLH (0.89) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL20630991 0.85 POLH (0.77) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL25865725 0.85 MEN1 (0.59) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL24497194 0.83 POLH (0.72) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL10728956 0.83 POLH (1.00) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL25304942 0.81 POLH (1.00) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL17620378 0.81 POLH (0.89) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL30663836 0.81 POLH (1.00) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL20630949 0.80 POLH (0.68) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL25262255 0.80 POLH (1.00) POLHMEN1KMT2AKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230372499-A1 DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY THE JOHNS HOPKINS UNIVERSITY 2023-11-23 — — US disclosed
US-20230233696-A1 TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF Ashvattha Therapeutics, Inc. (US) 2023-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372499-A1 DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TIE1, FLT3, FLT1 POLH 838/4885MEN1 651/4885KMT2A 247/4885
US-20230233696-A1 TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF FUT6, FUT5, OGT POLH 3085/4885MEN1 3004/4885KMT2A 2097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback